Centanafadine · Simtriyo
Small molecule
Evidence outlook
Approved: Attention Deficit Hyperactivity Disorder (label: Adults and pediatric patients 6 years and older weighing at least 20 kg)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03605680 NCT03605680 · Attention Deficit Hyperactivity Disorder This was a large randomized, double-blind, placebo-controlled trial, with 466 participants entering the treatment period and approximately 144–147 participants analyzed per group. The prespecified primary endpoint—a validated clinician-rated ADHD symptom scale—was significantly better with both centanafadine doses than with placebo at Day 42. Registry: NCT03605680 | 3 | Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) (Baseline and Day 42) 2020-04-11 | Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) (Baseline and Day 42): Double-blind Treatment Period: Centanafadine SR 200 mg -10.1 score on a scale (Standard Error 0.99) | Double-blind Treatment Period: Centanafadine SR 400 mg -9.73 score on a scale (Standard Error 0.98) | Double-blind Treatment Period: Placebo -6.98 score on a scale (Standard Error 0.98) | Reliable signal | link ↗ |
View 3 more trials
NCT03605836 NCT03605836 · Attention Deficit Hyperactivity Disorder The trial randomized 440 participants to centanafadine 200 mg, centanafadine 400 mg, or matching placebo in a double-blind design. The primary clinical symptom endpoint was met for both doses, with statistically significant improvement versus placebo. Registry: NCT03605836 | 3 | Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42 (Baseline and Day 42) 2020-05-14 | Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42 (Baseline and Day 42): Double-blind Treatment Period: Centanafadine SR 200 mg -12.1 score on a scale (Standard Error 0.96) | Double-blind Treatment Period: Centanafadine SR 400 mg -12.5 score on a scale (Standard Error 0.99) | Double-blind Treatment Period: Placebo -8.07 score on a scale (Standard Error 0.94) | Reliable signal | link ↗ |
NCT05257265 NCT05257265 · Attention Deficit Hyperactivity Disorder This was a well-designed, adequately powered (n=459) randomized, double-blind, placebo-controlled trial measuring a validated clinical symptom scale (ADHD-RS-5) as its primary endpoint. However, the result was mixed: only the higher of the two tested doses significantly beat placebo, while the lower dose failed to do so, so the trial did not deliver a clean positive result across its design. Registry: NCT05257265 | 3 | Attention-Deficit/Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5) (From baseline to week 6) 2023-09-29 | ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint | Partial signal | link ↗ |
NCT05428033 NCT05428033 · Attention Deficit Hyperactivity Disorder Registry: NCT05428033 | 3 | Attention-Deficit/Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5) Change from baseline in the ADHD-RS-5 symptoms total raw score (investigator interview with informant) at Week 6 (From baseline to week 6) 2025-03-17 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Serotonin/norepinephrine/dopamine transporter drugs
Ansofaxine hydrochloride, Liafensine. Compare all 3 Serotonin/norepinephrine/dopamine transporter drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Attention Deficit Hyperactivity Disorder: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Centanafadine (Simtriyo): this drug | Approved | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal | NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint | |
| Viloxazine (Qelbree) | Approved | Small molecule | norepinephrine transporter | Reliable signal | NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91) NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52) | |
| Ansofaxine Hydrochloride | Phase 3(overall) | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Solriamfetol (Sunosi) | Phase 3 | Small molecule | Dopamine/norepinephrine transporter | not yet graded | No reviewed efficacy summary in this indication | |
| Liafensine | Phase 2(overall) | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Lysergide Tartrate (LSD) (DT120) | Phase 2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| PDC-1421 | Phase 2 | Botanical | Polygalae radix extract (active components: tenuifolin, polygalasaponins, etc.) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Simtriyo (Centanafadine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (5)
May 2027 (1)
What to watch
August 2027 (2)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent